Introduction {#s0005}
============

Melanoma is generally managed successfully with surgical resection; however, advanced or metastatic disease is associated with poor prognosis [@bb0005]. Although the incidence of melanoma remains low in China, it is growing at an annual rate of 3--5%, and approximately 20,000 new cases are reported each year [@bb0005]. For patients with advanced melanoma, chemotherapy is often ineffective, and there is a paucity of second-line treatment options for patients with advanced disease in China. Use of immune checkpoint inhibitors has significantly improved survival outcomes in white patients with diagnoses of advanced or metastatic melanoma [@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]. Treatment with checkpoint inhibitors of Chinese patients with more aggressive melanoma subtypes has not been well characterized.

The subtypes of melanoma most common in Asian patients, unlike white patients, are acral and mucosal, and they account for up to 58% of all melanoma tumors in that patient population [@bb0035]. Acral and mucosal melanomas are more frequently characterized by DNA structural changes and mutation signatures of unknown etiology. Although cutaneous melanoma is characterized by defects in *BRAF, CDKN2A, NRAS,* and *TP53*, acral melanoma is associated with genetic mutations of *BRAF, NRAS, KIT*, *MAP2K2*, and *NF1,* and mucosal melanoma is associated with mutations of *SF3B1* [@bb0040]. Acral and mucosal melanomas are generally regarded as more aggressive [@bb0045]; in addition, because they manifest in hidden locations, these tumors often remain undiagnosed until they reach an advanced stage [@bb0050], [@bb0055]. In an analysis of 82 Chinese patients with acral (39.0%), nodular (37.8%), lentigo (12.2%), and superficial spreading (11.0%) melanoma, the 3- and 5-year survival rates were 39.0% and 10.9%, respectively [@bb0060]. To date, the antitumor activity of immunotherapeutic agents in this patient population has not been well characterized.

Pembrolizumab blocks the interaction between programmed death 1 (PD-1) and its ligands, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) [@bb0065]. Pembrolizumab demonstrated robust and efficacious antitumor tumor activity in the phase I KEYNOTE-001 study [@bb0070], [@bb0075], the phase II KEYNOTE-002 study [@bb0080], and the phase III KEYNOTE-006 study [@bb0085]. Pembrolizumab has been approved in more than 80 countries for the treatment of one or more malignancies, including melanoma. The efficacy of pembrolizumab in Asian populations has been assessed. In the phase Ib trial of pembrolizumab in Japanese patients with advanced melanoma (KEYNOTE-041), the objective response rate (ORR) in 42 patients who received treatment was 24.1% for cutaneous melanoma and 25.0% for mucosal melanoma [@bb0090]. In a Korean population of 37 patients who were treated with either pembrolizumab or nivolumab, the ORRs were 9.1% in cutaneous melanoma and 11.5% in acral/mucosal melanoma [@bb0095]. In 52 Chinese patients, the ORRs were 0%, 20%, and 25% for patients with advanced/metastatic disease treated with ipilimumab, pembrolizumab plus ipilimumab, and pembrolizumab monotherapy, respectively [@bb0045]. Nonetheless, further prospective reports assessing the treatment of Chinese patients with advanced melanoma are needed.

In this analysis, we present the first results of the KEYNOTE-151 trial ([NCT02821000](NCT02821000){#ir0010}), which evaluated the safety and efficacy of pembrolizumab in Chinese patients with advanced melanoma that progressed following first-line chemotherapy or targeted therapy.

Materials and methods {#s0010}
=====================

*Patients.*

KEYNOTE-151 was an open-label, nonrandomized, multicenter, phase Ib trial. Patients were ≥ 18 years of age, were of Chinese descent, and had histologically confirmed diagnoses of locally advanced or metastatic melanoma not amenable to local therapy. Patients were enrolled if their disease progressed on or after first-line chemotherapy (excluding adjuvant or neoadjuvant therapy) or targeted therapy for melanoma, if they had at least a measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, if they had an Eastern Cooperative Oncology Group performance status of 0 or 1, if they had a life expectancy ≥3 months, if they had provided tissue (archival, newly obtained, or excisional biopsy of a tumor lesion that was not previously irradiated) for evaluation of PD-L1 expression (patients were enrolled irrespective of PD-L1 expression status) and if they had known *BRAF* mutational status or were willing to provide tumor tissue for *BRAF* genotyping. Key exclusion criteria were diagnosis of uveal or ocular melanoma; previous therapy with an anti--PD-1, anti--PD-L1, or anti--PD-L2 agent; known active central nervous system tumors/metastases and/or carcinomatous meningitis; autoimmune disease that necessitated systemic treatment in the past 2 years; HIV positivity; history of (noninfectious) pneumonitis that necessitated treatment with steroids or current pneumonitis; and known active hepatitis B or C.

*Study Design and Assessments.*

Patients received pembrolizumab 2 mg/kg on day 1 of each 3-week cycle for up to 35 cycles (approximately 2 years). Pembrolizumab was administered intravenously over a 30-minute period and continued until disease progression, onset of unacceptable toxicities, investigator decision to discontinue treatment, or withdrawal of patient consent. The primary end points were ORR, defined as complete response (CR) or partial response (PR) based on RECIST v1.1 and assessed by blinded independent central radiology review (BICR), and safety and tolerability, assessed by clinical review of all relevant parameters including adverse event (AEs), laboratory tests, and vital signs. Secondary end points were duration of response (DOR; defined as the time from the first documented response to subsequent disease progression or death from any cause) per RECIST v1.1 by BICR and progression-free survival (PFS; defined as the time from the first day of study treatment to disease progression or death from any cause) per RECIST v1.1 and immune-related RECIST (irRECIST) by BICR, ORR per irRECIST by BICR, overall survival (OS; defined as the time from the first day of study treatment to death from any cause), and pharmacokinetics (PK). PD-L1 expression in tumor samples was assessed centrally using an immunohistochemistry assay, PD-L1 22C3 pharmDx (Agilent Technologies, Carpinteria, CA, USA). PD-L1 positivity was assessed using the Allred Proportion Score (APS) method in which positively stained mononuclear tumor-infiltrating inflammatory cells in immediate contact with tumor cells are counted in conjunction with neoplastic cells. PD-L1 positivity was defined as staining on at least 1% of tumor cells or mononuclear inflammatory cells within or contiguous to nests of tumor cells.

*Radiological disease assessment.*

A baseline imaging assessment was made within 4 weeks of the first dose of study treatment, and the first on-study imaging assessment was performed 12 weeks after the first dose of pembrolizumab. Subsequent imaging assessments were performed every 6 weeks (±7 days) until 48 weeks and then every 12 weeks (±7 days). Response was confirmed by subsequent imaging 4 weeks later or at the next scheduled scan (6 or 12 weeks later), as clinically indicated. Imaging was continued until disease progression, start of new anticancer therapy, withdrawal of consent, death, or study end (whichever occurred first).

*Statistical Assessments.*

The full-analysis set consisted of all allocated patients who received ≥1 dose of study treatment and had baseline data (measurable disease per RECIST v1.1 at baseline) for analyses that required baseline data. ORR and PFS were assessed in the full-analysis set; DOR was assessed in all responders; OS and safety were assessed in the all-subjects-as-treated population. ORR was evaluated by providing the point estimate and 95% confidence internal (CI) using an exact method based on binomial distribution. For PFS, DOR, and OS, Kaplan--Meier curves and median estimated from the curves were provided as appropriate. Summary statistics included count, percentage, mean, and standard deviation (SD). No adjustment was made for multiplicity. The planned sample size was 100 patients. The data cutoff was December 27, 2017 (per protocol, 24 weeks after last patient enrolled).

*Study Oversight.*

The original protocol and all amendments were approved by the relevant institutional review board or independent ethics committee at each trial center. The trial was conducted in accordance with the protocol, Good Clinical Practice guidelines, and the provisions of the Declaration of Helsinki. All patients provided written informed consent.

*Role of the Funding Source.*

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, sponsored this study. The sponsor collaborated with academic advisers to design the study and gather, analyze, and interpret the results. All authors had full access to all study data and approved the decision to submit the manuscript for publication.

Results {#s0015}
=======

*Patient Disposition and Demographics.*

KEYNOTE-151 enrolled 103 patients who were included in the all-subjects-as-treated population; 102 patients were included in the full-analysis set. Overall, 42.7% (*n* = 44) were male, the median age was 52 years (range, 22--77 years), 43.7% (*n* = 45) had an Eastern Cooperative Oncology Group performance status of 0, 53.4% (*n* = 55) had stage M1c disease, and 51.5% (*n* = 53) were PD-L1 positive ([Table 1](#t0005){ref-type="table"} [@bb0100]). Of those enrolled, 37.9% (*n* = 39) had acral melanoma and 14.6% (*n* = 15) had mucosal melanoma. Prior therapies included chemotherapy in 68.9% (*n* = 71), ipilimumab in 16.5% (*n* = 17), immunotherapy other than ipilimumab in 17.5% (*n* = 18), BRAF/MEK inhibitor in 2.9% (*n* = 3), and other in 31.1% (*n* = 32). As of the data cutoff of December 27, 2017, the median follow-up duration was 7.9 months (range, 5.6--13.1 months); 73.8% (*n* = 76) had discontinued treatment---60.2% (*n* = 62) because of progressive disease (PD), 8.7% (*n* = 9) because of clinical progression, 3.9% (*n* = 4) because of an AE---and 1.0% (*n* = 1) of patients withdrew. Treatment was ongoing in 26.2% (*n* = 27).Table 1Baseline characteristics.Table 1**Characteristicn (%)**\
***N* = 103**SexMale44 (42.7)Female59 (57.3)Age, years\<6584 (81.6)≥6519 (18.4)Mean50.5SD14.2Median52.0Range22 to 77ECOG performance status045 (43.7)158 (56.3)PD-L1 statusPositive53 (51.5)Negative45 (43.7)Unknown5 (4.9)HistologyCutaneous, nonacral41 (39.8)Cutaneous, acral39 (37.9)Mucosal15 (14.6)Primary site unknown8 (7.8)Metastatic stageM04 (3.9)M18 (7.8)M1A13 (12.6)M1B23 (22.3)M1C55 (53.4)Overall stage[a](#tf0005){ref-type="table-fn"}IIIC2 (1.9)III1 (1.0)IV100 (97.1)*BRAF* mutation statusWild type82 (79.6)Mutant20 (19.4)Unknown1 (1.0)Baseline lactate dehydrogenase levelNormal (\<1.1× ULN)70 (68.0)Elevated (≥1.1× ULN)33 (32.0)Brain metastasesYes2 (1.9)No101 (98.1)Baseline tumor size (mm)[b](#tf0010){ref-type="table-fn"}Mean86.1SD70.6Median60.8Range11.3 to 270.1Prior adjuvant/neoadjuvant therapyYes69 (67.0)No34 (33.0)Type of first-line therapy[c](#tf0015){ref-type="table-fn"}Chemotherapy71 (68.9)Ipilimumab17 (16.5)Immunotherapy (ipilimumab excluded)18 (17.5)BRAF/MEK inhibitor3 (2.9)Other32 (31.1)Type of prior adjuvant/neoadjuvant therapyChemotherapy14 (13.6)Immunotherapy (ipilimumab excluded)65 (63.1)Other5 (4.9)[^1][^2][^3][^4]

*Efficacy.*

Confirmed CR and PR were achieved in 1 (1.0%) and 16 (15.7%) patients, respectively, for an ORR per RECIST v1.1 of 16.7% (95% CI, 10.0--25.3%) ([Table 2](#t0010){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}). An additional 22 (21.6%) patients achieved stable disease for a disease control rate (defined as CR + PR + SD) of 38.2% (95% CI, 28.8--48.4%) during the overall treatment period. Overall, 36 patients (35.3%) experienced a reduction from baseline in the size of their target lesions ([Fig. 2](#f0010){ref-type="fig"}). The median time to response per RECIST v1.1 was 2.8 months (range, 2.6--9.7 months), and the median DOR was 8.4 months (1.1 + −11.0+ months). The DOR was ≥3 months in 87.5% and ≥ 6 months in 65.6% of patients. The median PFS per RECIST v1.1 was 2.8 months (95% CI, 2.7--3.5 months) ([Fig. 3](#f0015){ref-type="fig"}A). At 6 and 12 months, PFS rates were 20.4% and 11.9%, respectively. The confirmed ORR, the median DOR, and the median PFS were the same per RECIST v1.1 and irRECIST. At data cutoff, 45 (43.7%) deaths had been recorded. The estimated median OS was 12.1 months (95% CI, 9.6 months--not reached) ([Fig. 3](#f0015){ref-type="fig"}B). Six-month and 12-month OS rates were 75.7% and 50.6%, respectively.Table 2Objective responses[a](#tf0020){ref-type="table-fn"} for all patients and for the acral and mucosal subpopulations (full-analysis set).Table 2**All Patients**\
***N* = 102 (%)Acral**\
***n* = 38Mucosal**\
***n* = 15**CR1 (1.0)0 (0)1 (6.7)PR16 (15.7)6 (15.8)1 (6.7)**Objective response rate (CR + PR)17 (16.7)6 (15.8)2 (13.3)**SD22 (21.6)10 (26.3)1 (6.7)**Disease control rate (CR + PR + SD)39 (38.2)16 (42.1)3 (20.0)**Progressive disease52 (51.0)18 (47.4)8 (53.3)No assessment11 (10.8)4 (10.5)4 (26.7)[^5][^6]Fig. 1Duration of response based on RECIST v1.1 per BICR. *BICR*, blinded independent central review; *PD,* progressive disease; *PR,* partial response; *Q3W,* every 3 weeks; *RECIST,* Response Evaluation Criteria in Solid Tumors.Fig. 1Fig. 2Best percentage change in target lesion size from baseline based on RECIST v1.1 per BICR in the full-analysis set. Values ≥100 were set to 100. Data were not available for 13 patients (12.7%). *BICR*, blinded independent central review; *Q3W*, every 3 weeks; *RECIST,* Response Evaluation Criteria in Solid Tumors.Fig. 2Fig. 3Kaplan--Meier estimates of PFS (A) in the full-analysis set per BICR and OS (B) in all-patients-as-treated population. *BICR,* blinded independent central review; *OS*, overall survival; *PFS,* progression-free survival; *Q3W,* every 3 weeks.Fig. 3

*ORR by Subgroup.*

The ORR was 15.8% (95% CI, 6.0--31.3%) for the acral subtype, 19.5% (95% CI, 8.8--34.9%) for the non-acral subtype, 13.3% (95% CI, 1.7--40.5%) for the mucosal subtype, and 12.5% (95% CI, 0.3--52.7%) for primary site unknown subtypes. The ORR was 21.2% (95% CI, 11.1--34.7%) in patients with PD-L1--positive tumors and 13.3% (95% CI, 5.1--26.8%) in patients with PD-L1--negative tumors. The ORR was 15.0% (95% CI, 3.2--37.9%) in patients with *BRAF* mutant status and 17.3% (95% CI, 9.8--27.3%) in patients with *BRAF* wild-type status.

*Safety.*

TRAEs were reported in 84.5% (*n* = 87) of patients ([Table 3](#t0015){ref-type="table"}); the most common were hypothyroidism in 23.3% (*n* = 24), hypertriglyceridemia in 20.4% (n = 21), and increased blood lactate dehydrogenase in 15.5% (*n* = 16). Grade 3/4 TRAEs were reported in 8.7% (*n* = 9) of patients; of these, 1.9% (*n* = 2; autoimmune hepatitis, *n* = 1, and pneumonia, *n* = 1) of patients discontinued treatment. Two deaths were reported that were unrelated to study treatment; 1 death was a result of shock and 1 death was a result of pulmonary embolism. No patients died because of a TRAE.Table 3Treatment-related AEs occurring in ≥2% of patients.Table 3**Adverse Events, n (%)All Treated Patients**\
***N* = 103Any GradeGrade 3--5**Blood and lymphatic system disordersAnemia11 (10.7)5 (4.9)Endocrine disordersHypothyroidism24 (23.3)0Hyperthyroidism6 (5.8)0Autoimmune thyroiditis3 (2.9)0Gastrointestinal disordersNausea4 (3.9)0Diarrhea3 (2.9)0General disorders and administration site conditionsFatigue15 (14.6)1 (1.0)Asthenia6 (5.8)0Pyrexia4 (3.9)0Peripheral swelling3 (2.9)0Hepatobiliary disordersHepatic function abnormal4 (3.9)1 (1.0)Laboratory investigationsBlood lactate dehydrogenase increased16 (15.5)0Alanine aminotransferase increased15 (14.6)0Blood bilirubin increased11 (10.7)0Aspartate aminotransferase increased10 (9.7)0Bilirubin conjugated increased7 (6.8)2 (1.9)Blood creatine phosphokinase increased7 (6.8)0Blood cholesterol increased6 (5.8)0Blood bilirubin unconjugated increased5 (4.9)0Blood glucose increased5 (4.9)0Blood thyroid stimulating hormone increased5 (4.9)0Total bile acids increased5 (4.9)0Blood urea increased4 (3.9)0Blood uric acid increased4 (3.9)0Neutrophil count decreased10 (9.7)0Platelet count decreased3 (2.9)1 (1.0)Transaminases increased4 (3.9)0Weight decreased3 (2.9)1 (1.0)White blood cell count decreased12 (11.7)3 (2.9)Metabolism and nutrition disordersHypertriglyceridemia21 (20.4)0Hyperglycemia11 (10.7)0Hyperuricemia9 (8.7)0Decreased appetite8 (7.8)1 (1.0)Hypercholesterolemia5 (4.9)1 (1.0)Musculoskeletal and connective tissue disordersMyalgia4 (3.9)0Arthralgia3 (2.9)0Backpain3 (2.9)0Neoplasms benign, malignant, and unspecified^a^Tumor pain5 (4.9)0Nervous system disorders5 (4.9)0Renal and urinary disordersProteinuria4 (3.9)0Respiratory, thoracic and mediastinal disorders6 (5.8)0Skin and subcutaneous tissue disordersRash14 (13.6)0Pruritus11 (10.7)0Skin depigmentation4 (3.9)0Skin hypopigmentation4 (3.9)0[^7][^8]

Immune-mediated AEs were reported in 30 patients (29.1%) ([Table 4](#t0020){ref-type="table"}). The most frequently reported immune-mediated AEs were hypothyroidism (23.3%), hyperthyroidism (5.8%), and autoimmune thyroiditis (2.9%). Most cases of hypothyroidism were subclinical in nature, as diagnosed with thyroid function tests. Two patients (1.9%) experienced grade 3 or 4 immune-mediated AEs (rhabdomyolysis, grade 3; autoimmune hepatitis, grade 4). One patient discontinued study treatment because of autoimmune hepatitis. There were no infusion reactions.Table 4Immune-mediated AEs occurring in \>1% of the population.Table 4**Characteristic*n* (%)**\
***N* = 103**All grade, \>1% of patientsPatients with ≥1 immune-mediated AEs30 (29.1)Hypothyroidism24 (23.3)Hyperthyroidism6 (5.8)Autoimmune thyroiditis3 (2.9)Autoimmune hepatitis1 (1.0)Hypersensitivity1 (1.0)Rhabdomyolysis1 (1.0)Interstitial lung disease1 (1.0)[^9]

Discussion {#s0020}
==========

Chinese patients with locally advanced or metastatic melanoma who were treated with pembrolizumab had an ORR of 16.7% (95% CI, 10.0--25.3%). The ORRs in patients with acral and mucosal subtypes were similar, with rates of 15.8% (95% CI, 6.0--31.3%) and 13.3% (95% CI, 1.7--40.5%), respectively. Of the patients who responded in the total patient population, 65.6% (Kaplan--Meier estimate) had a response lasting ≥6 months. The estimated 6- and 12-month OS rates were 75.7% and 50.6%, respectively, and the plateau in the Kaplan--Meier curve suggests that pembrolizumab may provide Chinese patients with long-term survival benefit. These analyses of KEYNOTE-151 support the use of pembrolizumab for the treatment of Chinese patients with melanoma that progresses following first-line therapy.

The historical standard-of-care, first-line treatment for Chinese patients with advanced or metastatic melanoma has been dacarbazine, and its use has been associated with poor outcomes. Results of a phase II study in Chinese patients with advanced melanoma (*N* = 110; 42.6% and 13.0% had acral and mucosal melanoma, respectively) treated with first-line dacarbazine plus placebo experienced a median PFS of 1.5 months and a median OS of 8.0 months; ORR was 3.7% [@bb0105]. Patients in that trial who received the recombinant human endostatin ("endostar" plus dacarbazine) experienced a median PFS of 4.5 months and a median OS of 120 months [@bb0105]. The 12-month OS rate was 49.7% in the endostar/dacarbazine arm and 22.5% in the placebo/dacarbazine arm. Furthermore, no CRs were reported, and only 5 (8.9%) and 2 (3.7%) patients achieved PR in each arm. More recent trials have aimed to assess dacarbazine combination therapy with a variety of agents, including ipilimumab and BRAF inhibitors. However, in a pooled analysis of nine randomized controlled trials, combination therapy was associated with a higher incidence of AEs and only moderately improved outcomes compared with dacarbazine monotherapy [@bb0110]. Results of a phase Ib study of pembrolizumab in Japanese patients with advanced melanoma (*N* = 42) indicate that they experienced ORRs of 24.1% for cutaneous melanoma and 25.0% for mucosal melanoma [@bb0090]. Median OS was not reached; 12-month OS rates were 82.7% and 51.4% for patients with cutaneous and mucosal melanoma, respectively. In the analysis of KEYNOTE-151 presented herein, pembrolizumab was associated with a median OS of 12.1 months, with a 12-month survival rate of 50.6%; the ORR was 16.7%. Taken together, results of these studies indicate that Asian patients with advanced melanoma who are treated with pembrolizumab have better clinical outcomes in the second-line setting than patients treated with dacarbazine in the first-line setting.

Recently, vemurafenib was assessed in a phase I study that enrolled 46 treatment-naive or previously treated Chinese patients with *BRAF*^V600^ mutation--positive unresectable or metastatic melanoma [@bb0115]. Confirmed best ORR was 52.2%, median PFS was 8.3 months, and median OS was 13.5 months. Nine grade 3/4 AEs were reported in 7 patients (15.2%). Although BRAF inhibitors have high initial response rates in *BRAF*-mutant, metastatic melanoma, almost all patients who are treated with them ultimately become resistant. Consistent with this observation, approximately 50% of patients experience disease progression by 6 months [@bb0120]. The incidence of *BRAF* mutations in Chinese patients with melanoma (25.5%) [@bb0125] was much lower than that in the white patients (approximately 50%). For patients without *BRAF* mutations, the standard first-line therapy in China is still limited to dacarbazine. No effective second-line therapy is available.

In KEYNOTE-151, pembrolizumab had an acceptable safety profile for the treatment of Chinese patients with unresectable and metastatic melanoma. The safety of pembrolizumab in the current study was consistent with reports in white patients [@bb0075], [@bb0080], [@bb0085]. Most treatment-related AEs were low grade. Grade 3/4 treatment-related AEs were experienced in just 8.7% (*n* = 9) of patients, with less than 2% resulting in patient discontinuation and none resulting in death. In KEYNOTE-151, 29.1% of patients experienced immune-mediated AEs, which was similar to incidences reported in the global melanoma pivotal studies and the Japanese registration study [@bb0070], [@bb0080], [@bb0085], [@bb0090]. In the current study, the most common immune-mediated AEs were hypothyroidism (23.3%), hyperthyroidism (5.8%), and autoimmune thyroiditis (2.9%). Most cases of hypothyroidism were subclinical, based on results of thyroid function tests, and none of the patients required study treatment interruption or discontinuation. Some patients with hypothyroidism received hormone replacement therapy to manage their hypothyroidism (*n* = 6, 5.8%). None of the immune-mediated AEs led to death. No new safety signals or immune-mediated AEs associated with pembrolizumab were identified.

Given the lower incidence in white populations, limited data exist for acral and mucosal melanoma in Western populations. In an analysis of 1567 patients enrolled in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006, 84 (5%) had mucosal melanoma. Of these, the ORR was 19%, median PFS was 2.8 months, and median OS was 11.3 months [@bb0130]. In an additional multi-institutional retrospective analysis conducted in the United States in 60 patients with either acral (*n* = 25) or mucosal (*n* = 35) melanoma, 67% (*n* = 40) of patients received pembrolizumab and 33% (*n* = 20) received nivolumab for the treatment of advanced disease [@bb0135]. The ORR was 32% in the acral and 23% in the mucosal subgroups. After a median follow-up of 20 months (acral) and 10.6 months (mucosal), the median PFS was 4.1 months and 3.9 months, respectively. Median OS was 31.7 months in acral melanoma and not reported in mucosal melanoma because follow-up was not mature enough. Nonetheless, though these rates were comparable with those observed in cutaneous melanoma, the trial was limited by its retrospective nature. Furthermore, the data should be interpreted with caution because they were derived from a pooled analysis of varying doses and schedules. Results of a pooled analysis of data from 889 patients with mucosal (*n* = 86) or cutaneous (*n* = 665) melanoma treated with nivolumab monotherapy showed median PFS of 3.0 months and 6.2 months, respectively, and ORRs of 23.3% and 40.9%, respectively [@bb0140]. Data were also pooled for patients with mucosal (*n* = 35) or cutaneous (*n* = 326) melanoma treated with nivolumab combined with ipilimumab [@bb0140]. The combination showed greater activity than nivolumab monotherapy overall, but activity in mucosal melanoma was still lower than activity in cutaneous melanoma; median PFS was 5.9 months and 11.7 months respectively, and ORR was 37.1% and 60.4%, respectively. In KEYNOTE-151, we report an ORR of 15.8% in acral melanoma and 13.3% in mucosal melanoma. The ORRs by subtype were similar to those observed in the overall patient population (16.7%), supporting the use of PD-1 inhibition as second-line therapy, regardless of melanoma subtype.

In conclusion, the treatment of Chinese patients with advanced melanoma, particularly those with acral or mucosal subtypes, represents a strong unmet medical need. The standard of care for first-line treatment of Chinese patients with advanced melanoma is dacarbazine; there is no standard of care for second-line treatment. Poor survival outcomes have led to the recent exploration of immunomodulators in this population. In this first analysis of KEYNOTE-151, pembrolizumab was well tolerated, and ORRs in patients with acral or mucosal melanoma were similar to those in the overall patient population. Moreover, responses were durable, with a median DOR of 8.4 months and a median OS of 12.1 months. These data support the use of pembrolizumab for second-line treatment in Chinese patients with advanced or metastatic melanoma.
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[^1]: *ECOG,* Eastern Cooperative Oncology Group; *PD-L1,* programmed death ligand 1; *SD,* standard deviation; *ULN,* upper limit of normal.

[^2]: Per American Joint Committee on Cancer Staging Manual, version 7 [@bb0100].

[^3]: Data were missing for one patient.

[^4]: Some patients received more than one therapy in the first-line setting.

[^5]: *CR,* complete response; *PR,* partial response; *RECIST*, Response Evaluation Criteria in Solid Tumors; *SD,* stable disease.

[^6]: Based on RECIST v1.1 per blinded independent central review.

[^7]: *AE,* adverse event.

[^8]: ^a^Including cysts and polyps.

[^9]: *AE*, adverse event.
